4D Molecular Therapeutics Reports Positive Interim Data from 4D-710 Clinical Trial
4D Molecular Therapeutics announced positive interim clinical data from the 4D-710 Phase 1 AEROW clinical trial for the treatment of cystic fibrosis lung disease. AEROW Phase 1 Interim Data: No new pulmonary or other safety events occurred since previous update in higher-dose cohorts with up to 3.5 years of follow-up; In lower-dose cohorts, 4D-710-related adverse events were generally mild, transient and resolved by 2 months, with no 4D-710-related severe adverse events; Airway biopsy and brushing results demonstrated consistent and dose-dependent CFTR transgene RNA levels at or above physiologically relevant levels in non-CF control samples. In 2.5E14 vg dose cohort, results met target expression profile In 2.5E14 vg dose cohort, consistent evidence of clinically meaningful activity detected in all endpoints, including ppFEV1, LCI2.5 and quality of life through 1 year; Based on evaluation of safety, tissue expression and efficacy data, 2.5E14 vg was selected as the Phase 2 dose
Get Free Real-Time Notifications for Any Stock
Analyst Views on FDMT
About FDMT
About the author
4D Molecular Therapeutics Grants 23,600 RSUs to New Employees
- Employee Incentive Program: On January 13, 2026, 4D Molecular Therapeutics' compensation committee granted 23,600 Restricted Stock Units (RSUs) to four new non-executive employees, aimed at attracting talent and enhancing team stability.
- Equity Grant Context: The RSUs were awarded under the 2025 Employment Inducement Award Plan, approved by the board in February 2025, complying with Nasdaq Rule 5635(c)(4), reflecting the company's commitment to talent acquisition.
- Product Development Progress: The company's lead product, 4D-150, is currently in Phase 3 trials, designed to provide multi-year sustained delivery of anti-VEGF through a single safe intravitreal injection, significantly reducing the treatment burden associated with current methods, showcasing transformative potential.
- Gene Therapy Innovation: The second candidate, 4D-710, is the first known genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients, demonstrating the company's innovative capabilities and market potential in the therapeutic landscape.
Major Stocks Including BlackBerry, FedEx, and Nike Decline in Friday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are mostly higher, with Nasdaq 100 futures gaining around 100 points on Friday.
BlackBerry Earnings Report: BlackBerry Ltd reported third-quarter revenue of $141.8 million, exceeding analyst expectations, but shares fell 4.6% in pre-market trading.
Other Stocks Declining: Several stocks, including Aimei Health Technology and Nike Inc, experienced significant declines in pre-market trading despite some reporting better-than-expected earnings.
Market Overview: The overall market sentiment is cautious, with various stocks showing downward trends following recent earnings reports and inflation data.
